BioSpace News Archive

Precision Medical Products, the largest DVT (Deep Vein Thrombosis) medical device company in the nation, welcomes Dan Berish as its new President of Acute Care.

Noteworthy growth in the incidences of neurological disorders and autoimmune diseases across the globe is projected to help in the expansion of the global intravenous immunoglobulin market, according to a new study published by TMR.

Technological advancements in the medical industry have been key pivot for improving healthcare care delivery.

Transparency Market Research has recently published a new research report that talks about the overall landscape of the global empty capsules market.

During the 2nd quarter we significantly ramped up our pre commercial activities in the US following the strengthening of the team announced in Q1.

InDex Pharmaceuticals Holding AB announced that the company will conduct a clinical pharmacokinetic study with cobitolimod in Sweden.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of industry veteran William C. Fairey to its Board of Directors

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today.

A small exploratory clinical trial, carried out by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute in collaboration with researchers at Weill Cornell Medicine and Columbia University Irving Medical Center, suggests that benfotiamine, a synthetic precursor of thiamine (vitamin B1), has the potential to be an effective treatment or preventive measure for Alzheimer’s disease (AD).

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced the pricing of an underwritten public offering of 35,294,117 shares of common stock or common stock equivalents and investor warrants to purchase up to an aggregate of 35,294,117 shares of common stock.